The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.
 
Heikki Joensuu
Stock and Other Ownership Interests - Orion
Honoraria - ARIAD; Blueprint Medicines; Orion
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Orion
 
Pirkko-Liisa Kellokumpu-Lehtinen
Consulting or Advisory Role - Novartis; Pfizer; Roche/Genentech; Sanofi
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Roche/Genentech; Sanofi
 
Riikka Huovinen
No Relationships to Disclose
 
Arja Jukkola-Vuorinen
No Relationships to Disclose
 
Minna Tanner
Consulting or Advisory Role - Pfizer; Roche; Teva
Speakers' Bureau - AstraZeneca; Novartis; Roche
 
Riitta Kokko
No Relationships to Disclose
 
Päivi Auvinen
No Relationships to Disclose
 
Outi Lahdenperä
No Relationships to Disclose
 
Kenneth Villman
No Relationships to Disclose
 
Paul Nyandoto
No Relationships to Disclose
 
Greger Nilsson
Honoraria - Amgen; AstraZeneca; Eisai
 
Marja Murashev
No Relationships to Disclose
 
Paula Poikonen-Saksela
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Pierre Fabre; Sanofi
 
Petri Bono
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Orion; Pfizer
Research Funding - Novartis
 
Vesa Kataja
No Relationships to Disclose
 
Henrik Lindman
Consulting or Advisory Role - Amgen; Celgene; Pfizer